Providing clinically proven, innovative, nonsurgical treatments to improve women’s intimate health.
The Viveve System addresses medical conditions affecting a woman’s functionality and quality of life. The SINGLE-SESSION treatment is a MINIMALLY INVASIVE, COMFORTABLE approach to IMPROVING URINARY INCONTINENCE, VAGINAL LAXITY, SEXUAL FUNCTION OR BLOOD FLOW.*
The VIVEVE TREATMENT IS DELIVERED VIA THE VIVEVE SYSTEM, a patented, radiofrequency device that rebuilds natural collagen to improve the structural integrity of the vagina and to support the urethra. The treatment IMPROVES ORGASM, LUBRICATION AND AROUSAL and provides a structural foundation for the urethra, DECREASING URINE LEAKS.
Treatment
The Treatments Viveve Solutions help your patients feel like themselves again.
- The Viveve treatment has been clinically shown in multiple studies to improve lubrication, orgasm, and arousal4 and provides a structural foundation for the urethra.
- The only treatment developed specifically for women experiencing vaginal tissue changes due to childbirth, age, hormones or pelvic floor trauma.
- The Viveve Treatment is a 30-45 minute in office procedure.
- It is a comfortable, dignified treatment.
- Single-session for maximum ROI and patient convenience.
- Sustained results documented at 12 months
The Technology
The Only Energy-Based Device In Women’s Health Using Cryogen Cooling
Allows Sustained Time on Tissue and Ideal Depth of Penetration
- Cryogen Reverse Thermal Gradient– Three-phase continuous cooling protects the tissue closest to the treatment tip while heating the deeper tissues.
- Software – Automatically monitors temperature to consistently deliver cryogen and RF energy at 90J/cm2.
Match the technology to the issue and the tissue
- Patented Cryogen-cooled Monopolar Radiofrequency (CMRF) ideal for issues with tissue involvement requiring robust neocollagenesis.
The Science
Viveve I Clinical Study results published in The Journal of Sexual Medicine
- First and only multi-center, prospective, randomized, blinded, sham-controlled trial, using an energy-based procedure.
- Single treatment using cryogen-cooled monopolar radiofrequency (CMRF).
- 164 subjects
- No serious adverse events reported in Active group
- Statistically significant improvement in sexual function in Active group
- Likelihood of clinical endpoint more than three times greater for Active vs. Sham group at six months.
- Placebo effect in sham group began to diminish at three months.
“With Viveve, the thing that impressed me the most is that the science and the white papers were there before the direct to consumer campaigns”
– Dr. Francisco Canales
SUI ISRP* Feasibility Study– Interim Data
- Single 45-minute treatment using cryogen-cooled monopolar radiofrequency (CMRF)
- No device-related safety issues were reported in any of the patients
- 29 patients have completed 6-month visit
Clinically meaningful improvement in patient reported outcome
NOTES:
*ISRP- Investigator Sponsored Research Program
The light blue shaded areas in each figure denote a published minimal clinical important difference (MCID) denoted in the literature.
Data shared by the Allan Centre in Calgary, Alberta Canada